Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI; Southwest Oncology Group. Blayney DW, et al. Among authors: miller tp. J Clin Oncol. 2003 Jul 1;21(13):2466-73. doi: 10.1200/JCO.2003.06.137. J Clin Oncol. 2003. PMID: 12829664 Clinical Trial.
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.
Jones SE, Grozea PN, Miller TP, Van Slyck EJ, Balcerzak SP, Costanzi JJ, Morrison FS, Eyre HJ, Fabian CJ, Dabich L, et al. Jones SE, et al. Among authors: miller tp. J Clin Oncol. 1985 Oct;3(10):1318-24. doi: 10.1200/JCO.1985.3.10.1318. J Clin Oncol. 1985. PMID: 3900301 Clinical Trial.
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Fisher RI, et al. Among authors: miller tp. Ann Oncol. 1994;5 Suppl 2:91-5. doi: 10.1093/annonc/5.suppl_2.s91. Ann Oncol. 1994. PMID: 7515652 Clinical Trial.
A clinical phase II study of ProMACE-CytaBOM.
Dahlberg S, Miller TP, Fisher RI. Dahlberg S, et al. Among authors: miller tp. J Clin Oncol. 1991 May;9(5):888. J Clin Oncol. 1991. PMID: 1707958 No abstract available.
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI, Longo DL, DeVita VT Jr, Hubbard SM, Miller TP, Young RC. Fisher RI, et al. Among authors: miller tp. Ann Oncol. 1991 Jan;2 Suppl 1:33-5. doi: 10.1093/annonc/2.suppl_1.33. Ann Oncol. 1991. PMID: 1710487 Free article. Review.
255 results